Patients attending VA clinics may experience variability in testosterone prescribing practices for hypogonadism.
Low adherence to topical testosterone therapy has been linked to lowered total testosterone values and poor outcomes.
There has been growing concern that testosterone replacement therapy is associated with adverse cardiovascular outcomes.
Studies published in JAMA and JAMA Internal Medicine highlight the benefits and risks of treating men for low testosterone.
Researchers have pinpointed harmonized references ranges for total testosterone levels in men.
Starting testosterone treatment is associated with an increased risk of venous thromboembolism (VTE), peaking within 6 months and declining thereafter.
Men treated with implantable testosterone pellets have a statistically significant increase in mean hematocrit, but it is unlikely to be clinically relevant.
Once-daily testosterone solution 2% (T-sol) is safe and improves sex drive and energy in men with androgen deficiency.
Sexual function and mood and depressive symptoms were improved in older men who received testosterone therapy.
Acerus announced that its agreement with an affiliate of Endo International plc regarding the commercialization of Natesto (testosterone) nasal gel in the U.S. and Mexico will be terminated as of June 30, 2016.
American Association of Clinical Endocrinologists issues position statement on CV risks of testosterone therapy.
Experts suggest that more studies are necessary to evaluate testosterone therapy in men with age-related hypogonadism.
Researchers observed no impact on rate of change of intima-media thickness, coronary artery calcium score.
Quality studies are still needed to answer crucial questions about TRT and prostate cancer, cardiovascular risk.
These findings are based on data from more than 30,000 American men aged 40 years and older.
Undergoing testosterone replacement therapy didn't improve ejaculatory dysfunction in men with testosterone deficiency.
More than half have depression or depressive symptoms, and 25% are taking antidepressants.
Findings in older men with high cholesterol and low testosterone.
The benefits of testosterone therapy outweigh the risks, according to experts, and the FDA may need to rethink its stance.
High levels of free testosterone and bioavailable testosterone, and low levels of sex hormone-binding globulin, are tied to a decreased risk for erectile dysfunction.
New data from two studies indicate that testosterone therapy is not associated with cardiovascular risks, which challenges recent FDA decisions.
Three doses of testosterone nasal gel may help normalize testosterone levels in men with hypogonadism.
Devices include remote heartbeat monitor, fitness smart socks and devices for monitoring glucose.
In older men, testosterone levels directly linked to sexual activity, desire.
Increases in total testosterone levels, testosterone secretion index values in middle-aged men.
Low serum testosterone appears to be linked to adverse outcomes in men with type 2 diabetes.
Long-term testosterone therapy did not increase incidence of prostate cancer in hypogonadal men.
Testosterone testing appears to be increasing, especially among men with comorbidities associated with hypogonadism.
The presence of axillary hair or use of deoderant or antiperspirant did not affect the absorption of a testosterone solution.
Hypogonadism is disproportionately high in men with spinal cord injury, leading researchers to suggest a connection between the two conditions.
Endocrinology Advisor Articles
- Imaging Studies in Hypothyroidism Evaluation Linked to Unnecessary Risks
- Insulin Glargine Associated With Breast Cancer Risk in T2D
- Transoral Endoscopic Thyroidectomy Vestibular Approach: Safety and Outcomes
- Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes
- Improving Vascular Function in Pediatric T1D With Metformin
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- Lower Risk for SGLT2i-Associated Genitourinary Infection With DPP-4i
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- SSRIs and SNRIs Linked to Type 2 Diabetes in Children, Adolescents
- Increased Risk of Diabetes, Post-Diabetes Pneumonia for Patients With COPD
- Pancreatic Exocrine Dysfunction Occurs After Islet Autoimmunity in T1D
- T2D in African American Women Ups ER-negative Breast Cancer Risk
- High-Sensitivity CRP and LDL-C Predictive of Subsequent MACE in T2D
- Risks Associated With Denosumab Discontinuation